-

Alpha emitters for cancer treatment

Our vision
Link to Our vision

Our vision

Thor Medical will become a world-leading enabler for targeted cancer therapies

About Thor Medical ASA

Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies.

Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste.

Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED.

Read more
Illustration of alpha particles

Alpha emitters for cancer treatment

Radionuclide Therapy (RNT) or Radioligand Therapy (RLT) utilising alpha-particle emitters is a promising technology for cancer treatment with a strong growth.

Read more

News

Archive

Investor relations

We are committed to provide all shareholders and potential investors with relevant financial information in a consistent and transparent manner. Here you will find relevant information about Thor Medical.